GlassScriptPhysician profile
David Andrew O'Neill
NPI 1922092394
$7,805.27
in general payments reported to CMS, 2019-2025
50 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $1,059 · 2021: $1,979 · 2022: $1,018 · 2023: $955 · 2024: $823 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,018.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $911.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $819.35 | 2019-2025 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $794.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $610.36 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $448.76 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Amgen INC. | $348.11 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $282.66 | 2019-2025 | Mounjaro, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.24 | 2019-2025 | Jardiance, Ofev, Trijardy Xr |
| Bayer Healthcare Pharmaceuticals INC. | $218.60 | 2022-2025 | |
| Amarin Pharma, INC. | $159.42 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $158.69 | 2022 | |
| Zimmer Biomet Holdings, INC. | $141.97 | 2020 | |
| Allergan, INC. | $141.43 | 2019-2020 | |
| Dexcom, INC. | $130.36 | 2021-2024 | Dexcom G6 Transmitter |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David O'Neill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.